IGIvan Göcze

Ivan Göcze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ivan Göcze has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Renal Recovery after the Implementation of an Electronic Alert and Biomarker-Guided Kidney-Protection Strategy following Major Surgery

    by Laszlo Halmy, Joshua Riedel, Florian Zeman, Birgit Tege, Volker Linder, Carsten Gnewuch, Bernhard M. Graf, Hans J. Schlitt, Tobias Bergler, Ivan Göcze

    Background: The facilitation of early recovery of acute kidney injury (AKI) is an important step to improve outcome, particularly because of the limited therapeutic interventions currently available for AKI. The combination of an electronic alert and biomarker-guided kidney-protection strategy implemented in the routine care may have an impact on the incidence of early complete reversal of AKI after major non-cardiac surgery. Methods: We studied 294 patients in two cohorts before (n = 151) and after protocol implementation (n = 143). Data collection required 6 months for each cohort. The kidney-protection protocol included an electronic alert to detect patients who were eligible for urinary biomarker [TIMP2 × IGFBP7]-guided kidney-protection intervention. Intervention was stratified according to three levels of immediate AKI risk: low, moderate, and high. After intervention, postoperative changes in the glomerular filtration rate (eGFR) were identified with a tracking software that included an alert for nephrology consultation if the eGFR had declined by >25% from the preoperative reference value. Primary outcome was early AKI recovery, i.e., the complete reversal of any AKI stage to absence of AKI within the first 7 postoperative days. Results: Protocol implementation significantly increased the recovery of AKI (36/46, 78% compared to control 27/48, 56%, (p = 0.025)) and reduced the length of the ICU stay (p < 0.001). There was no significant difference in the overall incidence of all AKI and moderate and severe AKI in the first 7 postoperative days: 46/143 (32%) and 12/151 (8%) in the protocol implementation group compared to 48/151 (32%) and 18/151 (12%) in the historical control group. Patients with AKI reversal within the first 7 postoperative days had lower in-hospital mortality than patients without AKI reversal. Conclusions: Implementing a combined electronic alert and biomarker-guided kidney-protection strategy in routine care improved early recovery of AKI after major surgery.


  • Open Access

    Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel

    by Louis M. Guzzi, Tobias Bergler, Brian Binnall, Daniel T. Engelman, Lui Forni, Michael J. Germain, Eric Gluck, Ivan Göcze, Michael Joannidis, Jay L. Koyner, et al.

    The first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically available in many parts of the world, including the USA and Europe. We sought to understand how the test is currently being used clinically. We invited a group of experts knowledgeable on the utility of this test for kidney injury to a panel discussion regarding the appropriate use of the test. Specifically, we wanted to identify which patients would be appropriate for testing, how the results are interpreted, and what actions would be taken based on the results of the test. We used a modified Delphi method to prioritize specific populations for testing and actions based on biomarker test results. No attempt was made to evaluate the evidence in support of various actions however. Our results indicate that clinical experts have developed similar practice patterns for use of the [TIMP-2]•[IGFBP7] test in Europe and North America. Patients undergoing major surgery (both cardiac and non-cardiac), those who were hemodynamically unstable, or those with sepsis appear to be priority patient populations for testing kidney stress. It was agreed that, in patients who tested positive, management of potentially nephrotoxic drugs and fluids would be a priority. Patients who tested negative may be candidates for “fast-track” protocols. In the experience of our expert panel, biomarker testing has been a priority after major surgery, hemodynamic instability, or sepsis. Our panel members reported that a positive test prompts management of nephrotoxic drugs as well as fluids, while patients with negative results are considered to be excellent candidates for “fast-track” protocols.


  • Open Access

    Postoperative cellular stress in the kidney is associated with an early systemic γδ T-cell immune cell response

    by Ivan Göcze, Katharina Ehehalt, Florian Zeman, Paloma Riquelme, Karin Pfister, Bernhard M. Graf, Thomas Bein, Edward K. Geissler, Piotr Kasprzak, Hans J. Schlitt, et al.

    Basic science data suggest that acute kidney injury (AKI) induced by ischemia-reperfusion injury (IRI) is an inflammatory process involving the adaptive immune response. Little is known about the T-cell contribution in the very early phase, so we investigated if tubular cellular stress expressed by elevated cell cycle biomarkers is associated with early changes in circulating T-cell subsets, applying a bedside-to-bench approach. Our observational pilot study included 20 consecutive patients undergoing endovascular aortic repair for aortic aneurysms affecting the renal arteries, thereby requiring brief kidney hypoperfusion and reperfusion. Clinical-grade flow cytometry-based immune monitoring of peripheral immune cell populations was conducted perioperatively and linked to tubular cell stress biomarkers ([TIMP-2]•[IGFBP7]) immediately after surgery. To confirm clinical results and prove T-cell infiltration in the kidney, we simulated tubular cellular injury in an established mouse model of mild renal IRI. A significant correlation between tubular cell injury and a peripheral decline of γδ T cells, but no other T-cell subpopulation, was discovered within the first 24 hours (r = 0.53; p = 0.022). Turning to a mouse model of kidney warm IRI, a similar decrease in circulating γδ T cells was found and concomitantly was associated with a 6.65-fold increase in γδ T cells (p = 0.002) in the kidney tissue without alterations in other T-cell subsets, consistent with our human data. In search of a mechanistic driver of IRI, we found that the damage-associated molecule high-mobility group box 1 protein HMGB1 was significantly elevated in the peripheral blood of clinical study subjects after tubular cell injury (p = 0.019). Correspondingly, HMGB1 RNA content was significantly elevated in the murine kidney. Our investigation supports a hypothesis that γδ T cells are important in the very early phase of human AKI and should be considered when designing clinical trials aimed at preventing kidney damage. ClinicalTrials.gov, NCT01915446 . Registered on 5 Aug 2013.


  • Renal recovery

    by Ivan Göcze, Christina Wiesner, Hans J. Schlitt, Tobias Bergler


  • Die Herausforderung akute Nierenschädigung

    by I. Göcze, T. Bergler, E. Bossauer, F. Zeman, K. Thelen, B.M. Graf, B. Banas, H.J. Schlitt, W. Gnann, T. Bein

    Die akute Nierenschädigung [„acute kidney injury“ (AKI)] stellt eine häufige und schwerwiegende Komplikation bei kritisch kranken Patienten dar. Aktuelle Daten zur Prävalenz und den resultierenden Kosten der AKI sowie eine Übersicht zu den häufigsten AKI-assoziierten Diagnosen auf deutschen Intensivstationen fehlen. Es wurden alle erwachsenen Patienten (> 18 Jahre) auf den 5 Intensivstationen des Universitätsklinikums Regensburg (UKR; 78 Betten) mit einer codierten AKI im Zeitraum vom 1.1.2011 bis 31.12.2013 retrospektiv analysiert. Die Diagnosis-Related-Group(DRG)-relevanten Hauptdiagnosen mit der häufigsten AKI-Assoziation wurden ermittelt und die resultierende mittlere Verweildauer sowie die Sollkosten verglichen. Bei insgesamt 891 Patienten wurde die Diagnose AKI verschlüsselt [International Statistical Classification of Diseases (ICD-10)]. Ein akutes respiratorisches Versagen („acute respiratory distress syndrome“), Myokardinfarkt und Sepsis waren die 3 häufigsten mit einer AKI assoziierten DRG-relevanten Hauptdiagnosen. Insgesamt 1103 Patienten wurden mit einer der 3 o. g. Hauptdiagnosen auf den Intensivstationen des UKR behandelt. 249 Patienten (22,6 %) entwickelten eine AKI. Patienten mit AKI zeigten eine signifikant längere Intensiv- und Krankenhausverweildauer als Patienten ohne AKI (18,6 vs. 5,1 Tage und 23,8 vs. 10,4 Tage; p < 0,001). Das Auftreten einer AKI in diesen 3 Patientengruppen war im Jahr 2013 mit Behandlungsmehrkosten in Höhe von 2.019.120,42 € verbunden. Die AKI bei Intensivpatienten stellt ein schwerwiegendes medizinisches und sozioökonomisches Problem dar. Das koordinierte Vorgehen mit der Gründung eines nationalen AKI-Netzwerks zur Implementierung evidenzbasierter Therapien, die konsequente Früherkennung von AKI-Risikopatienten und eine intensivierte Suche nach neuen Therapieoptionen könnten die zukünftigen Schritte zur Reduktion der AKI-Inzidenz bzw. -Schwere und der Behandlungsmehrkosten darstellen.


  • Open Access

    Urinary Biomarkers TIMP-2 and IGFBP7 Early Predict Acute Kidney Injury after Major Surgery

    by Ivan Gocze, Matthias Koch, Philipp Renner, Florian Zeman, Bernhard M. Graf, Marc H. Dahlke, Michael Nerlich, Hans J. Schlitt, John A. Kellum, Thomas Bein

    To assess the ability of the urinary biomarkers IGFBP7 (insulin-like growth factor-binding protein 7) and TIMP-2 (tissue inhibitor of metalloproteinase 2) to early predict acute kidney injury (AKI) in high-risk surgical patients. Postoperative AKI is associated with an increase in short and long-term mortality. Using IGFBP7 and TIMP-2 for early detection of cellular kidney injury, thus allowing the early initiation of renal protection measures, may represent a new concept of evaluating renal function. In this prospective study, urinary [TIMP-2]×[IGFBP7] was measured in surgical patients at high risk for AKI. A predefined cut-off value of [TIMP-2]×[IGFBP7] >0.3 was used for assessing diagnostic accuracy. Perioperative characteristics were evaluated, and ROC analyses as well as logistic regression models of risk assessment were calculated with and without a [TIMP-2]×[IGFBP7] test. 107 patients were included in the study, of whom 45 (42%) developed AKI. The highest median values of biomarker were detected in septic, transplant and patients after hepatic surgery (1.24 vs 0.45 vs 0.47 ng/l2/1000). The area under receiving operating characteristic curve (AUC) for the risk of any AKI was 0.85, for early use of RRT 0.83 and for 28-day mortality 0.77. In a multivariable model with established perioperative risk factors, the [TIMP-2]×[IGFBP7] test was the strongest predictor of AKI and significantly improved the risk assessment (p<0.001). Urinary [TIMP-2]×[IGFBP7] test sufficiently detect patients with risk of AKI after major non-cardiac surgery. Due to its rapid responsiveness it extends the time frame for intervention to prevent development of AKI.


  • Simplified approach for the assessment of kidney perfusion and acute kidney injury at the bedside using contrast-enhanced ultrasound

    by Ivan Göcze, Philipp Renner, Bernhard M. Graf, Hans J. Schlitt, Thomas Bein, Karin Pfister